EuBiologics Past Earnings Performance
Past criteria checks 0/6
EuBiologics has been growing earnings at an average annual rate of 117.1%, while the Biotechs industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 25.7% per year.
Key information
117.1%
Earnings growth rate
131.4%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 25.7% |
| Return on equity | -14.7% |
| Net Margin | -20.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How EuBiologics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 69,366 | -13,879 | 7,449 | 17,882 |
| 30 Sep 23 | 59,892 | -4,361 | 7,445 | 21,616 |
| 30 Jun 23 | 61,222 | -1,010 | 8,378 | 20,689 |
| 31 Mar 23 | 59,140 | -1,323 | 10,617 | 18,993 |
| 31 Dec 22 | 55,467 | -1,099 | 10,543 | 15,777 |
| 30 Sep 22 | 50,472 | 2,022 | 9,340 | 15,249 |
| 30 Jun 22 | 48,534 | 3,808 | 7,617 | 14,796 |
| 31 Mar 22 | 42,810 | -24,462 | 6,810 | 14,198 |
| 31 Dec 21 | 39,385 | -27,574 | 5,701 | 16,178 |
| 31 Dec 20 | 28,490 | -60,134 | 3,884 | 8,504 |
Quality Earnings: A206650 is currently unprofitable.
Growing Profit Margin: A206650 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if A206650's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare A206650's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A206650 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).
Return on Equity
High ROE: A206650 has a negative Return on Equity (-14.65%), as it is currently unprofitable.